Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.69 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.69 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | UMPS | P11172 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789899 | 1.00 | P2RY6 (0.69) | P2RY6P2RY14NT5EDNPH1P2RY1 | |
| SCHEMBL27686864 | 0.89 | P2RY6 (0.80) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL668874 | 0.89 | P2RY6 (0.80) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL465109 | 0.89 | P2RY6 (0.80) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| Lithium Ion SCHEMBL29357540 | 0.88 | P2RY6 (0.79) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL9681927 | 0.84 | P2RY6 (0.81) | P2RY6P2RY14NT5EDNPH1 | |
| SCHEMBL7600836 | 0.84 | P2RY6 (0.66) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL7996435 | 0.84 | P2RY6 (0.66) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL9551479 | 0.83 | P2RY6 (0.77) | P2RY6P2RY14NT5EDNPH1 | |
| SCHEMBL1874190 | 0.83 | P2RY1 (0.81) | P2RY6P2RY14P2RY1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180339055-A1 | BONE TARGETED THERAPEUTICS AND METHODS OF MAKING AND USING THE SAME | MBC PHARMA INC (US) | 2018-11-29 | — | — | US | disclosed |
| US-20160095932-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9216204-B2 | Bone targeted therapeutics and methods of making and using the same | MBC PHARMA, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140051625-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8586781-B2 | Bone targeted therapeutics and methods of making and using the same | MBC PHARMA, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1383510-B1 | BISPHOSPHONATE CONJUGATES AND METHODS OF MAKING AND USING THE SAME | MBC PHARMA INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2260852-A2 | Bisphosphonate conjugates and methods of making and using the same | MBC Pharma, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7598246-B2 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090227544-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-6896871-B2 | Biphosphonate conjugates and methods of making and using the same | MBC RESEARCH, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1383510-A4 | BISPHOSPHONATE CONJUGATES AND METHODS OF MAKING AND USING THE SAME | MBC RES INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050026864-A1 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6750340-B2 | A BISPHOSPHONATE COMPOUND CONJUGATED WITH ANTIBIOTIC, NUCLEOSIDE, ANTISENSE NUCLEIC ACID AND OTHER DRUGS CAPABLE OF RELEASING ANTIBIOTIC OR CYTOTOXIC COMPONENT UPON BINDING WITH BONE TISSUE; USEFUL FOR TREATING BONE CANCER AND INFECTION | MBC RESEARCH, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1383510-A1 | BISPHOSPHONATE CONJUGATES AND METHODS OF MAKING AND USING THE SAME | MBC Research, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002083150-A1 | BISPHOSPHONATE CONJUGATES AND METHODS OF MAKING AND USING THE SAME | MBC RESEARCH, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020142994-A1 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. | 2002-10-03 | — | — | US | disclosed |
| US-20010041689-A1 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. | 2001-11-15 | — | — | US | disclosed |
| US-6214812-B1 | VITAMIN B6 BISPHOSPHONATE CONJUGATE | MBC RESEARCH, INC. | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051625-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | P2RY6 131/4885P2RY14 797/4885NT5E 230/4885 |
| US-20010041689-A1 | Bisphosphonate conjugates and methods of making and using the same | SOST, BPGM, PTH1R | P2RY6 540/4885P2RY14 1661/4885NT5E 310/4885 |
| US-20020142994-A1 | Bisphosphonate conjugates and methods of making and using the same | SOST, BPGM, PTH1R | P2RY6 540/4885P2RY14 1661/4885NT5E 310/4885 |
| US-20050026864-A1 | Bisphosphonate conjugates and methods of making and using the same | BPGM, SOST, ENPP2 | P2RY6 127/4885P2RY14 804/4885NT5E 251/4885 |
| US-20090227544-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | P2RY6 131/4885P2RY14 797/4885NT5E 230/4885 |
| US-20160095932-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | P2RY6 131/4885P2RY14 797/4885NT5E 230/4885 |
| US-20180339055-A1 | BONE TARGETED THERAPEUTICS AND METHODS OF MAKING AND USING THE SAME | SOST, BPGM, BST2 | P2RY6 131/4885P2RY14 797/4885NT5E 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.